Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Upgraded by Wall Street Zen

Oramed Pharmaceuticals (NASDAQ:ORMP) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings upgraded Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 11th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold”.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ:ORMP opened at $4.48 on Friday. The firm’s 50 day simple moving average is $4.18 and its 200-day simple moving average is $3.84. Oramed Pharmaceuticals has a one year low of $1.98 and a one year high of $5.19. The firm has a market cap of $186.37 million, a PE ratio of 1.09 and a beta of 1.22.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.43 by ($0.52). Equities research analysts predict that Oramed Pharmaceuticals will post 1.24 EPS for the current fiscal year.

Insider Activity

In other Oramed Pharmaceuticals news, COO Joshua Hexter sold 137,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.46, for a total transaction of $611,020.00. Following the sale, the chief operating officer owned 1,023,384 shares of the company’s stock, valued at approximately $4,564,292.64. The trade was a 11.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Avraham Gabay sold 73,360 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.51, for a total transaction of $330,853.60. Following the transaction, the chief financial officer owned 671,785 shares in the company, valued at $3,029,750.35. The trade was a 9.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ORMP. Kathmere Capital Management LLC acquired a new position in Oramed Pharmaceuticals during the first quarter valued at $51,000. OMERS ADMINISTRATION Corp purchased a new stake in Oramed Pharmaceuticals in the 1st quarter worth $63,000. Redwood Family Wealth LLC purchased a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth about $66,000. XTX Topco Ltd lifted its position in shares of Oramed Pharmaceuticals by 59.9% in the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 14,297 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in Oramed Pharmaceuticals during the 4th quarter worth $119,000. Hedge funds and other institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.